Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses methods to further reduce DHT in the scalp for hair loss treatment, with users suggesting various approaches like using dutasteride, minoxidil, tretinoin, and natural supplements like pumpkin seed oil. Some users also mention using topical applications and scalp massages to enhance the effectiveness of these treatments.

User TopBack56 and friends tried pyrilutamide (KX-826) for hair loss without experiencing negative side effects. They observed fine vellus hairs but no thick hair growth yet, and plan to add GT20029 to their regime after safety trials.

Tressless GPT is now free and accessible for hair loss advice. Treatments discussed include Minoxidil, finasteride, RU58841, dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

The user is exploring alternatives to hair transplants due to a weak donor area and is currently using finasteride, minoxidil, dermapen, low-level laser therapy, Nizoral shampoo, and a high-protein diet. They plan to switch to dutasteride and consider adding RU58841, while rejecting hair systems and considering a buzz cut.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

The conversation discusses various hair loss treatments, with a focus on pyrilutamide, minoxidil, and alternatives to finasteride due to intolerance. Users suggest adding a DHT blocker like finasteride or dutasteride, and some recommend trying topical versions to reduce side effects.

Topilutamide is a potential hair loss treatment between Clascoterone and RU58841. Users discuss finding Topilutamide powder and its possible benefits for those who can't afford or tolerate other treatments.

Finasteride is a controversial hair loss treatment, with some users experiencing positive results and others facing side effects like erectile dysfunction. The discussion emphasizes the importance of personal choice and informed decision-making.

The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgen receptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.

Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.

The conversation is about someone considering stopping their hair loss treatment, which includes minoxidil, finasteride, ketoconazole, microneedling, and oral minoxidil, due to lack of visible results. Replies suggest continuing treatment, considering a hair transplant, and trying dutasteride.

RU58841 is a strong non-steroidal antiandrogen for hair loss but may cause cardiovascular issues in some users. Alternatives like Pyrilutamide and Breezula are suggested due to better safety profiles and lower systemic risks.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

Current treatments like finasteride, minoxidil, and derma rolling are considered the best for hair loss, while new treatments such as GT20029, PP405, and others are in various trial phases with results expected in the coming years. There is cautious optimism about the affordability and effectiveness of these upcoming treatments.

The conversation discusses hair loss treatments, focusing on Tsuji's hair cloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.

The user asks if finasteride can be used with the topical steroid betamethasone dipropionate to reduce hair loss and scalp inflammation. The discussion revolves around combining these treatments for better results.

A user who has been using Pyrilutamide for 5 months with no results, and other users suggesting they switch to RU58841 or stick to their treatment plan for at least one year.

A user suggests that deeper microneedling with Verteporfin injections might help regrow hair in areas with scar tissue, alongside a DHT blocker. Another user explains that hair loss might be due to reduced Wnt/β-Catenin signaling and suggests that treatments like Minoxidil, Finasteride, and microneedling could potentially reverse it.

Pyrilutamide phase 3 results showed little to no significant hair regrowth, but may be sufficient for maintaining current hair density. The user is unsure due to lack of recent discussions on pyrilutamide.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

The conversation introduces a specialized chatbot for ChatGPT Plus users that provides advice on hair loss treatments, drawing from research and community insights. It mentions treatments like RU58841, the "big 4" (likely minoxidil, finasteride, ketoconazole, and tretinoin), dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.

Tretinoin may enhance minoxidil's effectiveness for those not responding to minoxidil alone, but it could reduce efficacy for some who are already responding to minoxidil. Tretinoin requires careful use, including skin moisturizing and sun protection due to increased sensitivity.

A potential update on the progress of pyrilutamide, a hair loss treatment; and if Kintor should stop their trials.

The user has severe diffuse thinning on the scalp and is using finasteride, topical minoxidil, dermarolling, tretinoin, and Nizoral without satisfactory results. They are considering a hair transplant but are concerned about the cost and the number of grafts needed.

The conversation discusses aggressive hair loss treatments, including finasteride, dutasteride, minoxidil, topical cetirizine, and experimental options like Estrogel, oh-flutamide, and RU58841. Users share experiences and suggest trying oral minoxidil and el cranell, noting the complexity and challenges of treating hair loss.

The user stopped using Alfatradiol after 4 months due to no hair improvement and side effects like dry scalp and gallbladder pain. They are considering trying topilutamide, which is suggested as an alternative.